0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > News > Abveris and ACROBiosystems extend partnership to accelerate the pace of antibody discovery research
Abveris and ACROBiosystems extend partnership to accelerate the pace of antibody discovery research
Release time: 2020-04-08 Source: ACRO Read: 699


Newark, DE, USA and Canton, MA, USA, April 2, 2020 - ACROBiosystems, Inc., an internationally recognized manufacturer of recombinant proteins, today announced the extension of a strategic collaboration with Abveris, Inc., a leader in contract research antibody discovery. Under the terms of the agreement, the companies will leverage their core technologies to construct streamlined offerings to accelerate the pace of antibody discovery research.


By the terms of the agreement, over 1600 recombinant proteins for biologic drug discovery and development available in the ACROBiosystems catalog will be made available to Abveris customers to facilitate rapid initiation of antibody discovery projects.  1600+ reagents at your fingertips!



"Our collaboration with ACROBiosystems is a highly valuable resource for Abveris and all of our partner companies,”  commented Ryan Kelly, Director of Business Development at Abveris. "Our access to ACRO’s high-quality “off-the-shelf” reagents allows us to identify diverse, high affinity antibody clones in as little as one month total.  Start your antibody discovery project today!



“We are delighted to collaborate with Abveris, who shows their expertise in therapeutic antibody development. Their special DiversimAbTM platform and single B cell screening platform speed up the antibody generation process while providing maximum diversity and affinity of the antibody candidates. It delivers additional benefits and comforts to scientists with using ACRO’s high-quality reagents and Abveris’s technologies as a combination.” commented Simin He, Marketing Manager at ACROBiosystems.


1586339983330440.png

About ACROBiosystems: ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and solution based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. Check out more details at www.acrobiosystems.com.


屏幕快照 2020-04-08 下午11.17.02.png

About Abveris: Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.


Contact for ACROBiosystems:

            Grace Wang

            Marketing Specialist

            Grace.wang@acrobiosystems.com

            408-320-2195


Contact for Abveris:

            Ryan Kelly

            Director of Business Development

            rkelly@abverisantibody.com

            781-562-1170 x1002



This web search service is supported by Google Inc.

totop